The Interplay between Chronic Kidney Disease and Cardiovascular Disease: Mechanisms, Biomarkers, and Management

Abstract

Chronic kidney disease (CKD) and cardiovascular disease (CVD) share a bidirectional relationship that accelerates global morbidity and mortality. This review synthesizes the mechanisms underlying cardiorenal syndrome, highlights advance in diagnostic biomarkers and evaluates both established and emerging therapeutic strategies for managing the CKD–CVD interplay. Literature from PubMed, Scopus, and Google Scholar databases (2000-2025) was systematically searched for human studies on heart–kidney physiology, CKD-driven cardiovascular complications, biomarker development, and therapeutic interventions. CKD significantly increases 
cardiovascular risk via pathophysiological processes including persistent hypertension, oxidative stress, systemic inflammation, endothelial dysfunction, vascular calcification, and uremic toxin accumulation. The spectrum of cardiorenal syndrome (types 1–5) underscores the intricacy of cardiorenal crosstalk. Advances in biomarker research, notably serum creatinine, cystatin C (CysC), neutrophil gelatinase-associated lipocalin (NGAL), and metabolomic profiling have enabled more precise risk assessment and early detection. Traditional approaches focus on blood pressure control and proteinuria reduction through renin–angiotensin–aldosterone system (RAAS) blockade, mineralocorticoid antagonism, and diuretic use. Novel therapies seek to target disease drivers including fibrotic transformation, inflammation, and gut–kidney axis disruption. The reciprocal relationship between CKD and CVD demands early recognition, adoption of innovative biomarkers, and application of integrative management strategies. Enhancing disease awareness and fostering multidisciplinary care are vital to alleviating the global impact of cardiorenal syndrome.